Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)

FDA provided critical guidance for the advancement of CAD-1005 to pivotal Phase 3 in HIT Phase 2 data showed a greater than 25% absolute reduction in thrombotic events when CAD-1005 was added to standard anticoagulant therapy PONTE VEDRA, Fla., April 30, 2026 (GLOBE...

read more

Reviva Announces Letter to Shareholders

CUPERTINO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) ("Reviva," the "Company" "we" or "us"), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...

read more

ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors

PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette...

read more

Intelligent Protection Management Corp. to Participate in “Powering the AI Revolution” Virtual Conference Presented by Maxim Group LLC on Tuesday, April 7th at 10:30 a.m. EDT

JERICHO, NY / ACCESS Newswire / April 6, 2026 / Intelligent Protection Management Corp. ("IPM," "we," "us," "our" or the "Company") (NASDAQ:IPM), a managed technology solutions provider focused on enterprise cybersecurity and cloud infrastructure, announced today that...

read more
Skip to content